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Update on viral hemorrhagic fevers
R. Swanepoel
University of Pretoria, Pretoria, South Africa
Viral hemorrhagic fevers (VHF) are characterized by a propen-
sity for human-to-human spread and high death rates; properties
which render them liable to control by the state and necessitate
the use of high security laboratories for handling the etiological
agents. However, not all strains of the viruses concerned cause
hemorrhagic signs or highly lethal disease, while a variety of other
pathogens pose equally hazardous health problems. Hence, for
regulatory purposes it has been found more logical to classify
high consequence pathogens according to deﬁned biorisk groups.
Among the familiar VHFs of Africa, Marburg and Ebola ﬁloviruses
have been less active recently than 5-10 years ago, but there have
been advances in understanding the ecology and pathogenesis of
these viruses, and in developing candidate vaccines and therapeu-
tics. Meantime, the emergence of new pathogens has continued
apace, including a new arenavirus and a rhabdovirus causing hem-
orrhagic fever in Africa, and a phlebovirus in China.
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Etioepidemiology of dengue in Latin America
B. Zambrano
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Dengue is a mosquito-borne viral disease. It is estimated that
50-100 million people are infected and a half a million cases due
to DHF/DSS and ≈25,000 deaths occur annually worldwide. The
region of the Americas have experienced a dramatic increase in
the number of reported cases over the last thirty years, evolv-
ing from a low to a high endemicity situation, with indigenous
transmission in almost all countries. The 4 dengue serotypes are
circulating in the region, sometimes with a hyperendemic pattern
(co-circulation of 2 or more serotypes) in countries like Venezuela
and Colombia. Epidemic patterns of 3-5 years have been observed,
with an increasing number of reported cases in the last 5 years.
Caseshavebeen reportedwith a seasonality pattern related to rainy
season in most of countries. There is a trend of severe cases in
younger ages in the last 10 years in Latin America, compared to
what had been observed previously. To 15 Nov 2013, record ﬁg-
ures of more than 2 million of dengue cases had been reported to
PAHO (Pan American Health Organization), 32,270 of them con-
sidered as severe, the incidence rate was of 404.35 per 100,000
population, 1,175 deaths and case fatality rate of 0.05 Somemacro-
determinant factorsmay contribute to the increasing dengue cases,
like: Unprecedented population growth, unplanned and uncon-
trolled urbanization, increasing poverty, population movement
(migration, tourism), climatic change. Countries continue with the
efforts for the disease control through speciﬁc actions against
Aedes mosquitoes and PAHO’s Integrated Management Strategy
for dengue prevention and control, however additional measures
should be implemented like the development of effective dengue
vaccines to reinforce the current strategies
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The spread of dengue into Africa
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Prevention of dengue vaccines in the pipeline
L.C. Rey
Federal University of Ceara, Fortaleza CE, Brazil
Dengue burden is an important issue in Africa, Asia and the
Americas, with nearly 2 billion people exposed. Vector control is so
far the onlymeasure availableworldwide to stop the growingnum-
ber of cases. But control measures are not effective, since trends of
erratic urbanization and its consequences like water supply and
storage, and waste disposal, largely favors the mosquito spread-
ing. Vaccination is the most promising preventive intervention
and deserves heavy efforts. Denguevirus is a member of Flavivirus
Genus, andmanyof its componentshavebeen successfully targeted
for vaccine development, such as West Nile fever (veterinary),
Japanese encephalitis, tick-borne encephalitis andyellow fever, but
none of these viruses has four serotypes as denguevirus. Single
serotype (monovalent) dengue vaccines has been pursued since
the 1950s in Asia, when viral attenuation was obtained in sev-
eral mouse brain tissue passages, but a tetravalent vaccine was
never come to trial. Latter in the 1980s, natural attenuation process
in cell culture (PDK cells) gave rise to new live vaccines, through
the cooperation of Mahidol University in Thailand and the Walter
Reed Institute ofUSA.Monovalent PDK cell vaccineswere immuno-
genic, but when all four serotypes were put together interference
among serotypes appeared; two of these vaccines have been aban-
